The above chart presents the market trend analysis for kyongbo pharmaceutical co.ltd. from 2025 to 2026.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2026, the company has completed 6 transactions, with a transaction quantity of 1265 and a transaction weight of 0.1.
YearTransactionsQuantityWeight
2025224449.154.1
2026612650.1
Bill of lading data
<
1/15
>
Trade date
2026/03/30
B/L No.
108098719960
Suppliers
kyongbo pharmaceutical co.ltd.
Buyers
công ty cổ phần dược phẩm tenamyd
Product description
TEGAFUR,nguyên liệu là dược chất,BTP để sản xuất thuốc,CTHH:C8H9FN2O3,là hợp chất có chứa một vòng pyrimidin chưa hydro hóa trong cấu trúc,Batch no:F100500, NSX:27/1/2026,HSD:26/01/2029. Mới 100%
Expand
Trade date
2026/02/03
B/L No.
107954987340
Suppliers
kyongbo pharmaceutical co.ltd.
Buyers
công ty cổ phần dược phẩm tenamyd
Product description
Oteracil Potassium,nguyên liệu là dược chất,BTP để sản xuất thuốc,CTHH:C4H2KN3O4,là hợp chất có chứa một vòng Triazin chưa ngưng tụ chưa hydro hóa,Batch no:E200400, NSX:6/6/2025,HSD:5/6/2030. Mới 100%
Expand
Trade date
2025/11/03
B/L No.
107669714940
Suppliers
kyongbo pharmaceutical co.ltd.
Buyers
công ty cổ phần dược phẩm tenamyd
5ооо альфарма
russiabuyer,they trade on 2011-04-19
140.67%
>
+View All
Products
Total 9
ProductsTransactionsPerDetail
ceftriaxone sodium 2376.67%>
entercavir 2376.67%>
neomycin sulphate 2376.67%>
ceftriaxone sodium sterile 26.67%>
bitter 13.33%>
+View All
Hscode rank
Total 63
HSCode NameTransactionsPerDetail
HS 294190002376.67%>
HS 2941909026.67%>
HS 2915909013.33%>
HS 293339980013.33%>
HS 2934999013.33%>
+View All
Trading Area
Total 12
AreaTransactionsPerDetail
vietnam1024.86%>
indonesia602.86%>
russia592.81%>
uzbekistan140.67%>
pakistan120.57%>
+View All
Port statistics
Total 15
Port NameTransactionsPerDetail
incheon442.10%>
incheon kr311.48%>
incheon intl apt seoul170.81%>
busan60.29%>
inchon50.24%>
+View All
kyongbo pharmaceutical co.ltd. is International Buyer&Supplier,
and primarily engages in the import and export business of products such as ceftriaxone sodium,entercavir,neomycin sulphate.
According to the 52wmb.com global trade database, as of 2026-03-30, the company has completed 2100 international trades,
with its main trading regions covering vietnam,indonesia,russia etc.
The core products include HS29419000,HS29419090,HS29159090 etc,
often transported via incheon,port incheon kr, port incheon intl apt seoul etc,
and its main trading partners are pt menjangan sakti,tenamyd pharmaceutical corp.,pt.dexa medica.
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on kyongbo pharmaceutical co.ltd. is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.